Voriconazole,a novel triazole antifungal,was developed in an effort to address the needs unmet by currently available antifungals.It has excellent in vitro activity against both Candida and Aspergillus species.And it showed a good antifungal activity against fluconazole-resistant,itraconazole-resistant species.The mechanism of action,in vitro activity,in vivo activity,pharmacokinetics,drug interactions,clinical trials,safety,and adverse effects of voriconzole,a novel antifungal,are reviewed in this paper. |
[1] 刘康. 三唑类抗真菌药Voriconazole. 药学进展2002(4). doi:10.3969/j.issn.1001-5094.2002.04.024
[2] 马培奇. 第二代三唑类抗真菌新药伏立康唑. 国外医药(抗生素分册)2002(2). doi:10.3969/j.issn.1001-8751.2002.02.011
[3] 孙春林. 伏立康唑. 中国新药杂志2002(12)
[4] GuptaAK, TOMAS E. New antifungal agents, 2003(3)
[5] FLOREA N R, KUTI J L, QUINTILIANE R. Voriconazole:a novel azole antifungal, 2002
[6] SABO J A, ABDEL-RAHMAN S M. Voriconazole:a new triazole antifungal. 2000(9). doi:10.1345/aph.19237
[7] Jeu L, PIACENTI F J, LYAKHOVETSKIY A G. Voriconazole. 2003(5)
[8] CHANDRASEKAR P H, MANAVATHU E. Voriconazole:a second-generation triazole, 2001(2)
[9] BARCHIESI F, RESTREPO M, MCGOUGH D A. In vitro activity of a new antifungal triazole:UK-109,496, 1995
[10] DENNING D, RIBAUD P, MILPIED N. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. 2002(5)
[11] HITCHCOCK C A, ANDREWS R J, LEWIS B G. UK-109,496,a novel,wide-spectrum triazole derivative for the treatment of fungal infections:antifungal activity in experimental infections with aspergillus, 1995
[12] TROKE P F, BRAMMER K W, HITCHCOCK C A. UK-109,496,a novel,wide-spectrum triazole derivative for the treatment of fungal infections:activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candiasis (OPC), 1995
[13] HITCHCOCK C A, ANDREWS R J, LEWIS B G. UK-109,496,a novel,wide-spectrum triazole derivative for the treatment of fungal infections:antifungal activity in experimental infections with cryptococcus, 1995
[14] PYE G W, OLIVER G P, TROKE P F. UK-109,496,a novel,wide-spectrum triazole derivative for the treatment of fungal infections:antifungal activity and selectivity in vitro, 1995
[15] Ruhnke M, SCHMIDT W A, TRAUTMANN M. In vitro activities of Voriconazole (UK-109,496) against fluconazole-susceptible and -resistant candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection, 1997(3)
[16] CHANDRASEKAR P H, CUTRIGHT J, MANAVATHU E. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. 2002(5). doi:10.1093/jac/45.5.673
[17] LAIARUS H M, BLUMER J L, YANOVICH S. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection:a dose escalation study. 2002(4). doi:10.1177/0091270002424005
[18] Purkins L, WOOD N, GHAHRMANI P. Pharmacokinetics and safety of Voriconazole following intravenous-to oral-dose escalation regimens. 2002(8). doi:10.1128/AAC.46.8.2546-2553.2002
[19] Ghahramani P, ROMERO A, ALLEN M. The effect of voriconazole on the pharmacokinetics of cyclosporin, 2000
[20] GHAHRAMANI P, PRUKINS L, KLEINERMANS D. Effects of rifampicin and rifabutin on the pharmacokinetics of voriconazole, 2000
[21] GHAHRAMANI P, PRUKINS L, LOVE E. Drug interactions between voriconazole and phenytoin, 2000
[22] HAHRAMANI P, PRUKINS L, KLEINERMANS D. Effect of omeprazole on the pharmacokinetics of voriconazole, 2000
[23] CHANDRASEKAR P H, MANAVATHU E, VORICONAZOLE A. Second-generation trizole, 2001(2)
[24] YUET W. Voriconazole versus amphotericin for primary therapy of invasive aspergillosis. 2002(6). doi:10.1056/NEJMoa020191
[25] HOFFMAN H L, RATHBURN R C. Review of the safety and efficacy of voriconazole. 2002(11). doi:10.1517/13543784.11.3.409
[26] POTOSKI B A, BROWN J. The safety of voriconazole, 2002(10)
[27] ULLMANN A J. Review of the safety,tolerability,and drug interactions of the new antifungal agents caspofungin and voriconazole. 2003(4). doi:10.1185/030079903125001884 |
